Every patient is under the care of a radiation oncologist who is a cancer specialist with expertise in the application of radiation therapy as it is used in the management of cancer.

Phone
850-747-6972
Fax
850-747-6584
BRCC is part of a national exclusive group of centers where cancer patients are approved to enroll on Radiation Therapy Oncology Group (RTOG) protocols. Our collaboration through the RTOG brings us in communication with nationally recognized experts at major academic cancer centers. This helps Dr. Murshed to remain abreast of the most upto-date treatments for his patients. Dr. Murshed is an active participant in national RTOG clincial trials which enables his patients to receive the most upto-date and innovative treatment possible in a community setting in Panama City, FL.
To know more about RTOG please follow the link: RTOG Homepage
Clinical Trials Available at Panama City Oncology
Brain
1. RTOG 0837: Conventional chemoradiation & Temozolomide plus Cediranib vs. conventional chemoradiation & Temozolomide plus placebo for newly diagnosed GlioblastomaHead & Neck
1. RTOG 0920: Phase III study of post op IMRT +/- Cetuximab for locally advanced resected head and neck cancerLung
1. RTOG 0617: Stage IIIA/IIIB NSCL ca; Must be inoperable and unresectable; exclude pt w/N3 supraclavicular disease
2. 1RTOG 0937: Randomized phase II study comparing prophylactic cranial irradiation alone to prophylactic cranial irradiation and consolidative extra cranial irradiation for extensive disease small cell lung cancer (ED-SCLC)Gastrointestinal
1. RTOG 0848: Phase III trial evaluating both Erlotinib and chemoradiation as adjuvant for patients with resected head of pancreasGenito-urinary
1. RTOG 0815: A phase III randomized trial of dose-escalated radiotherapy with or without short-term androgen deprivation therapy for patients with intermediate-risk prostate cancer
2. RTOG 0534: A phase III trial of short term androgen deprivation with pelvic lymph node or prostate bed only radiotherapy (SPPORT) in prostate cancer patients with a rising PSA after radical prostatectomy.Gynecological
1. RTOG 0921: A phase II study of postoperative IMRT w/concurrent Cisplatin & Bevacizumab followed by Carboplatin & Paclitaxel for pt w/ endometrial cancer
2. GOG 0258: Randomized phase III trial of Cisplatin tumor volume directed irradiation followed by Carboplatin & Paclitaxel vs. Carboplatin & Paclitaxel for optimally debulked advanced endometrial cancer. Stage III or IVA endometrial carcinoma with no spread outside pelvis. Surgery: hysterectomy w/bilateral salpingo-opphorectormy